Thesis: argenx is the best-shaped name to fall out of the IBB breadth breakdown — a profitable FcRn-franchise leader compounding revenue +64% YoY in a clean golden-cross uptrend, and at RSI 62 it has more room than any other IBB leader on the board.

Verdict: Trend-hold-eligible / BUY-eligible, conviction MEDIUM (positive lean). ARGX is the cleanest single name surfaced by the IBB all-time-high breadth-decomposition work: profitable, +64% revenue growth, 100% beat rate, strong-up trend, golden cross active, near 52wk highs — and crucially RSI 62, not overbought like the RSI 77-78 leaders (RVMD/NTRA). This is a confirmed secular uptrend, not a falling knife. Caveats that hold conviction at MEDIUM rather than HIGH: a premium multiple, light volume on the recent push (relative volume 0.67), and IFRS/ADR reporting that leaves EDGAR XBRL partial.

The Story Right Now

argenx came out of the IBB breadth-decomposition investigation as a coverage gap — a top-6 holding in iShares' Nasdaq Biotechnology ETF at roughly 3.5% weight that we had not tracked, just added to the new ibb watchlist. IBB itself is at an all-time high led by mid-cap and biotech breadth while three mega-cap anchors (GILD/REGN/ALNY) lag. Inside that move, ARGX is both a leader and the best-structured one.

The tape backs it. Settled Friday 2026-06-26: price $912.46, RSI 62, trend strong-up, golden cross active (SMA50 above SMA200, price above all three). Price sits +4.7% over the SMA20 ($871.83), +9.9% over the SMA50 ($830.49), +11.9% over the SMA200 ($815.25). Returns run +9.13% over 30d, +29.55% over 3m, +67.89% over 1y, and price is only −2.37% off its 52wk high. The push has been on light participation, though — relative volume 0.67, with VWAP back at $771.17.

The fundamental spine is the FcRn-inhibitor franchise: Vyvgart / efgartigimod, anchored in myasthenia gravis with an expanding indication footprint. The company is now IFRS-profitable (FY2025 diluted EPS €19.57 $19.57 — correction 2026-08-03: argenx presents its financials in US dollars; the 20-F tags this figure USD/share, the euro sign was ours, not the filer's) and compounding revenue — a rare combination in biotech where most of the breadth leaders are still pre-profit.

Setup

• Entry zone: Buy strength — RSI 62 leaves room before overbought — or wait for a shallow pullback toward the rising SMA20 (~$872). Near 52wk highs but not extended.
• Stop: Below the SMA50 ($830); a clean break voids the uptrend structure. SMA200 ($815) is the deeper line.
• Target: Fresh highs / trend continuation. Trail it — no fixed number.
• Conviction: MEDIUM (positive lean).
• Sizing: Standard trend-hold starter; the premium multiple and light recent volume argue for a measured initial size and adding on confirmation rather than a full position into strength.

Bull case

• Profitable and compounding. FY2025 diluted EPS $19.57 (USD) with revenue growth YoY +64.3% — growth-stock economics with a real bottom line, unusual among the IBB breadth leaders.
• Cleanest shape on the board. Strong-up trend, golden cross active, price above SMA20/50/200, near 52wk highs, RSI only 62. The least-extended leader versus the RSI 77-78 names — more room and a less crowded entry.
• Reliable results. Leading-indicator earnings read STRONG with a 100% beat rate — the execution track record supports buying continuation rather than fading the move.
• Franchise breadth. FcRn / efgartigimod (Vyvgart) is an autoimmune platform, not a single-indication bet; indication expansion is the multi-year growth engine.
• Index tailwind. A top-6 IBB constituent (~3.5%) riding an ETF at all-time highs gets passive-flow support as breadth holds.

Bear case

• Premium multiple. The stock prices in continued execution; any growth wobble re-rates a rich name hard. This is the main reason conviction sits at MEDIUM.
• Light volume on the push. relative volume 0.67 means the recent advance has thin participation — less conviction behind the move, more vulnerable to a fast unwind.
• Reporting opacity. A Belgian IFRS filer trading as a US-listed ADR (NASDAQ: ARGX); EDGAR XBRL is partial and dated, so the clean GAAP detail we'd want for a US operating company is not fully available.
• Single-franchise concentration. Dependence on the FcRn franchise means competitive entrants or an indication setback hit a large share of the thesis.
• Per-period growth-rate flag. On a QoQ-rate basis the leading-indicator growth flag reads bearish even as the YoY figure is +64% — worth watching for an actual deceleration, not just a base effect.

Catalysts

• Next quarterly report. The next readout on Vyvgart / efgartigimod revenue and the beat-rate streak; results carry the trend here given the franchise's growth slope.
• Indication-expansion readouts. Further FcRn-franchise data and label-expansion milestones — the next readout on each new indication is the multi-year growth driver.
• IBB breadth durability. Whether mid-cap/biotech breadth keeps leading the ETF; a rotation back into the lagging mega-cap anchors would soften the passive-flow tailwind.
• Trend integrity. Hold above the SMA20/50 keeps the structure intact; a clean loss of the SMA50 (~$830) is the signal to stand down.

Financials

Source: SEC EDGAR XBRL. IFRS/ADR caveat: argenx is a Belgian IFRS filer listed as a US ADR, so its EDGAR XBRL is partial and dated — older line items appear stale and are reported in EUR. We do not present a clean GAAP table here; the table above leans on the FY2025 EPS and the leading-indicator reads rather than a full reconciled statement.

Leading-indicator read (leading ARGX): composite Neutral (0.1). The standout is the earnings signal — STRONG with a 100% beat rate — alongside revenue growth YoY +64.3%. Note the two-window split: the per-period flag reads bearish on a QoQ-rate basis while the YoY figure is strongly positive at +64%; both are true, and the QoQ-rate flag is the one to watch for a genuine deceleration rather than a base effect. Insider trading reads Neutral.

Balance-sheet note: Cash shows €366M as of 2025Q2 in the partial EDGAR record. argenx has historically been well-capitalized, so treat the exact figure as indicative rather than current — the IFRS/ADR XBRL gap means the cash line here is dated, not a runway concern.

Cross-references

• The June 29 IBB breadth-decomposition investigation — the parent work that surfaced ARGX as a top-6 IBB leader and coverage gap.
• ibb watchlist — ARGX newly added here; this deep dive closes the coverage gap.
• Sibling IBB leaders RVMD / NTRA (RSI 77-78) — the overbought comparison that makes ARGX's RSI 62 the cleaner entry.

Sources

• Price truth: summaries (settled Fri 2026-06-26 close) — price $912.46, RSI 62, trend strong-up, golden cross active; SMA20 $871.83 / SMA50 $830.49 / SMA200 $815.25; 30d +9.13%, 3m +29.55%, 1y +67.89%, −2.37% off 52wk high; VWAP $771.17, relative volume 0.67.
• Financials: the desk's own tooling (SEC EDGAR XBRL — IFRS/ADR partial, see caveat) — FY2025 diluted EPS $19.57 (USD/share per the 20-F); cash €366M (2025Q2, EUR-tagged, partial).
• Leading-indicator read: leading ARGX — composite Neutral (0.1); revenue growth YoY +64.3%; earnings STRONG, 100% beat rate; insider trading Neutral.